{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["49(5)"],"submitter":["Hagman E"],"pubmed_abstract":["<h4>Background</h4>The integration of mobile health technology with physical visits shows promising one-year treatment outcomes, but long-term evidence is lacking.<h4>Objectives</h4>To assess three-year treatment outcomes for patients utilizing the digital treatment tool Evira in combination with physical visits, compared with standard obesity care.<h4>Methods</h4>In a pragmatic trial, children with obesity aged 4.0-17.9 years receiving digi-physical treatment with Evira (n = 107) were compared with a group receiving standard treatment (n = 321). Evira comprises a digitless body scale for home-weighing, a mobile application, and a web-based clinic interface, enabling easy family-clinic communication and continuous visual treatment feedback.<h4>Results</h4>At the three-year follow-up, the a"],"journal":["International journal of obesity (2005)"],"pagination":["973-976"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12095034"],"repository":["biostudies-literature"],"pubmed_title":["Long-term results of a digital treatment tool as an add-on to pediatric obesity lifestyle treatment: a 3-year pragmatic clinical trial."],"pmcid":["PMC12095034"],"pubmed_authors":["Hagman E","Putri RR","Lindberg L","Drangel A","Danielsson P","Marcus C"],"additional_accession":[]},"is_claimable":false,"name":"Long-term results of a digital treatment tool as an add-on to pediatric obesity lifestyle treatment: a 3-year pragmatic clinical trial.","description":"<h4>Background</h4>The integration of mobile health technology with physical visits shows promising one-year treatment outcomes, but long-term evidence is lacking.<h4>Objectives</h4>To assess three-year treatment outcomes for patients utilizing the digital treatment tool Evira in combination with physical visits, compared with standard obesity care.<h4>Methods</h4>In a pragmatic trial, children with obesity aged 4.0-17.9 years receiving digi-physical treatment with Evira (n = 107) were compared with a group receiving standard treatment (n = 321). Evira comprises a digitless body scale for home-weighing, a mobile application, and a web-based clinic interface, enabling easy family-clinic communication and continuous visual treatment feedback.<h4>Results</h4>At the three-year follow-up, the a","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-06-01T19:15:31.353Z","creation":"2026-05-21T03:08:47.963Z"},"accession":"S-EPMC12095034","cross_references":{"pubmed":["40075128"],"doi":["10.1038/s41366-025-01738-0"]}}